clinical trial · NCT05289271
Safety, Tolerability, and Immunogenicity of Vaxelis™ in Children Previously Vaccinated With Vaxelis™ or Hexyon™ (V419-016)
Merck Sharp & Dohme LLC·phase4·completed·n = 168
Vaccines, CombinedHexavalent VaccineVaxelis™
brief summary
The primary objectives of this study are to evaluate the safety, tolerability, and immunogenicity of a booster dose of Vaxelis™ (V419) given at \~11 to 13 months of age in healthy participants who were previously vaccinated with a 2-dose primary infant series of either Vaxelis™ or Hexyon™.
started
Mar 25, 2022
primary completion
Aug 30, 2022
completion
Aug 30, 2022
last updated
Jul 29, 2024
official title
A Phase 4, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, and Immunogenicity of Vaxelis™ in Healthy Children Previously Vaccinated With a 2-Dose Primary Infant Series of Either Vaxelis™ or Hexyon™
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol